|Bid||0.7000 x N/A|
|Ask||0.7200 x N/A|
|Day's Range||0.7000 - 0.7300|
|52 Week Range||0.4050 - 2.4500|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr. 29, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.10|
Has finalized the study design and protocol for a Phase 1 clinical trial on a naturally derived Psilocybin ...
Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a leader in psychedelics-focused mental healthcare, is pleased to have finalized the study design and protocol for a Phase 1 clinical trial on a naturally derived Psilocybin extract, previously announced on April 26, 2021. This major milestone advances Numinus' investigation of its first proprietary psychedelic product, which was developed using a patent-pending technology submitted to the US Patent and Trade Office.
Virtual Investor Conferences in partnership with KCSA Strategic Communications today announced the presentations from the KCSA Psychedelics Virtual Investor Conference are now available for on-demand viewing.